Aptevo Therapeutics Inc.
APVO· Nasdaq
APVOAptevo Therapeutics Inc.
Filed May 13, 2026 · 10-Q · 43 days after period end · 0001193125-26-221661
| Metric | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 |
|---|---|---|---|---|
| Net Income | -$6.70M | -$6.41M | -$6.83M | $2.77M |
| EPS Diluted | -$6.41 | -$1,581.81 | -$368.21 | $17.38 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Aptevo Therapeutics Inc. · CIK 1671584 · Engraved from SEC EDGAR
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end
